Sound's for hearing loss: Co's drug wins FDA breakthrough tag for Meniere’s disease
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Roche says the move marks a step forward in its digital transformation strategy
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Subscribe To Our Newsletter & Stay Updated